Related Experiment Video
Updated: Aug 18, 2026
Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors
Published on: July 17, 2020
Pituitary tumor-transforming gene (PTTG): a novel target for anti-tumor therapy
Christine Solbach1, Marc Roller, Silke Peters
1Department of Gynecology and Obstetrics, Johann Wolfgang Goethe University, School of Medicine, Frankfurt am Main, Germany. Solbach@em.uni-frankfurt.de
Background:
The proto-oncogene pituitary tumor-transforming gene (PTTG) is described as abundantly over-expressed in a variety of neoplasms with impact on neovascularization and tumor invasiveness. Based on these findings, we raised the question as to whether PTTG is a target for an anti-tumor therapy.
Materials And Methods:
To investigate the impact of PTTG depletion on the human cervical cancer cell line HELA-S3, we used antisense-oligodesoxynucleotides (antisense-ODNs) and subjected them to in vitro transfection experiments. The PTTG mRNA level was determined by RT-PCR (45 cycles) and PTTG protein levels were determined by Western blot experiments. The impact of PTTG depletion on cell growth was determined 24, 48 and 72 hours post transfection by the trypan blue exclusion method.
Results:
We found an antisense-ODN effective in down-regulation of PTTG mRNA and protein level. Furthermore, transfection resulted in a significant growth inhibitory effect as well as an increased level of apoptotic figures.
Conclusion:
Our studies revealed an anti-tumor potential for this target in cancer therapy.
Insights
Targeting the pituitary tumor-transforming gene (PTTG) with antisense-oligodeoxynucleotides (antisense-ODNs) effectively reduced PTTG levels in cervical cancer cells. This PTTG depletion significantly inhibited tumor cell growth and increased apoptosis, suggesting PTTG as a potential anti-cancer therapy target.
Area of Science:
- Oncology
- Molecular Biology
- Gene Therapy
Background:
- Pituitary tumor-transforming gene (PTTG) is over-expressed in various cancers.
- PTTG influences tumor neovascularization and invasiveness.
- PTTG is a potential target for anti-cancer therapies.
Purpose of the Study:
- To investigate the impact of PTTG depletion on human cervical cancer cells (HELA-S3).
- To assess the therapeutic potential of targeting PTTG in cancer treatment.
Main Methods:
- Utilized antisense-oligodeoxynucleotides (antisense-ODNs) for PTTG depletion via in vitro transfection.
- Quantified PTTG mRNA levels using RT-PCR.
- Determined PTTG protein levels via Western blot.
- Assessed cell growth inhibition using the trypan blue exclusion method at 24, 48, and 72 hours post-transfection.
Main Results:
- Successfully down-regulated PTTG mRNA and protein levels using antisense-ODNs.
- Observed significant inhibition of cervical cancer cell growth post-transfection.
- Detected an increased level of apoptotic figures in treated cells.
Conclusions:
- PTTG depletion demonstrates significant anti-tumor effects in cervical cancer cells.
- These findings highlight PTTG as a promising target for novel cancer therapies.
More Related Videos
06:15Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
09:37Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
Published on: August 25, 2021
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...